



Affiliate of ProMedica

Criteria: P0270
Approved: 9/2019
Verified: 9/2019
Reviewed:

Prior Authorization Criteria Form

This form applies to Paramount Advantage and Paramount Commercial Members Only

VERZENIO

Complete/review information, sign and date. Please fax signed forms to Paramount at **1-844-256-2025**. You may contact Paramount by phone at **1-419-887-2520** with questions regarding the Prior Authorization process. When conditions are met, we will authorize the coverage of Verzenio.

Drug Name (select from list of drugs shown)

Verzenio (abemaciclib)

Quantity _____ Frequency _____ Strength _____
Route of Administration _____ Expected Length of Therapy _____

Patient Information

Patient Name: _____
Patient ID: _____
Patient Group No.: _____
Patient DOB: _____
Patient Phone: _____

Prescribing Physician

Physician Name: _____
Physician Phone: _____
Physician Fax: _____
Physician Address: _____
City, State, Zip: _____

Diagnosis: _____ ICD Code: _____

Comments: _____

Please circle the appropriate answer for each question.

- | | |
|---|-------|
| 1. Does the patient have a diagnosis of advanced or metastatic breast cancer?
[If no, no further questions.] | Y N |
| 2. Does the patient have hormone receptor (HR)-positive breast cancer?
[If no, no further questions.] | Y N |
| 3. Does the patient have human epidermal growth factor receptor 2 (HER2)-negative breast cancer?
[If no, no further question.] | Y N |
| 4. Will the requested drug be used in combination with fulvestrant?
[If no, skip to question 6.] | Y N |

- | | | |
|---|---|---|
| 5. Did the patient experience disease progression following endocrine therapy?
[No further questions.] | Y | N |
| 6. Will the requested drug be used as a single agent?
[If no, skip to question 9.] | Y | N |
| 7. Did the patient experience disease progression following endocrine therapy?
[If no, no further questions.] | Y | N |
| 8. Did the patient experience disease progression following prior chemotherapy in the metastatic setting?
[No further questions.] | Y | N |
| 9. Will the requested drug be used in combination with an aromatase inhibitor as initial endocrine-based therapy?
[If no, no further questions.] | Y | N |
| 10. Is the patient post-menopausal? | Y | N |

I affirm that the information given on this form is true and accurate as of this date.

Prescriber (Or Authorized) Signature and Date